Last updated: February 19, 2026
This report details the patent landscape and claim scope of JP2021517128, a Japanese patent application concerning a pharmaceutical compound and its therapeutic applications. The analysis identifies key claim elements, potential patentability challenges, and the competitive environment.
What is the Core Invention of JP2021517128?
JP2021517128 claims a novel compound, specifically a substituted pyrazolopyrimidine derivative, and its use in treating specific medical conditions. The patent application focuses on the chemical structure of the compound and its pharmacological activity.
The primary objective of the invention is to provide a therapeutically effective agent for conditions such as inflammatory diseases, autoimmune disorders, and certain types of cancer. The application discloses specific examples of the compound, denoted as Compound A, and provides data on its inhibitory activity against key biological targets associated with these diseases.
Key structural features of the claimed compound include:
- A pyrazolopyrimidine core.
- Specific substituent groups at defined positions on the pyrazolopyrimidine ring.
- An aryl or heteroaryl group attached to a side chain.
The patent application also covers pharmaceutical compositions containing the claimed compound, methods of treating diseases using these compounds, and specific dosages.
What is the Claimed Scope of Protection?
The claims in JP2021517128 are structured to provide broad protection for the novel chemical entity and its therapeutic uses.
Independent Claims:
- Claim 1: This claim defines the core chemical structure of the compound. It specifies a generic formula with designated positions for various substituents (R1, R2, R3, R4, R5). The substituents are defined by a list of possible chemical groups, including alkyl, aryl, heteroaryl, amino, and alkoxy groups. The exact nature and combination of these substituents determine the specific compound falling under this claim.
- Claim 7: This claim covers a pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier. This claim aims to protect the formulation aspect of the drug.
- Claim 12: This claim pertains to a method of treating a disease, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to Claim 1. The diseases mentioned include inflammatory diseases, autoimmune disorders, and neoplastic diseases.
Dependent Claims:
Dependent claims refine and narrow the scope of the independent claims. Examples include:
- Claims specifying particular examples of the substituents defined in Claim 1, thus claiming specific compounds that are embodiments of the generic formula.
- Claims specifying particular diseases to be treated, such as rheumatoid arthritis, psoriasis, or specific types of leukemia.
- Claims detailing specific carriers or excipients in the pharmaceutical composition.
- Claims defining specific dosage ranges.
The precise wording of these claims dictates the boundaries of the patent protection. For example, if Claim 1 defines R1 as a "substituted phenyl group," the patent will cover all compounds where R1 is a phenyl group with any of the listed substituents. However, if a competitor has a prior patent on a compound with a specific R1 group that fits within this definition, that compound may be excluded from the scope.
What is the Patent Landscape for Similar Compounds?
The patent landscape for substituted pyrazolopyrimidine derivatives is highly competitive, with numerous patents and applications filed globally. This indicates significant research and development activity in this chemical space.
Key Competitors and Their Patents:
Several major pharmaceutical companies and research institutions have active patents and patent applications related to pyrazolopyrimidine compounds for therapeutic use. These include:
- Pfizer Inc.: Has a portfolio of patents covering pyrazolopyrimidine derivatives for kinase inhibition, particularly relevant for oncology and inflammatory diseases.
- Novartis AG: Holds patents related to similar chemical scaffolds for treating autoimmune conditions and chronic inflammatory diseases.
- Bristol-Myers Squibb Company: Has research and patent filings focused on small molecule inhibitors, including pyrazolopyrimidine-based compounds, for various therapeutic targets.
- Various Biotech Companies: Smaller and mid-sized biotech firms are also actively pursuing patent protection for novel pyrazolopyrimidine derivatives.
Patent Filing Trends:
The trend in patent filings for this class of compounds shows a consistent increase over the past decade, driven by advances in medicinal chemistry and a better understanding of disease pathways. Japan, along with the United States, Europe, and China, represents a key jurisdiction for patent filings in this area.
Areas of Overlap and Potential Conflicts:
Potential patent conflicts arise when new patent applications claim compounds or uses that are already covered by existing patents. JP2021517128’s claims will be examined against prior art, which includes:
- Known chemical structures: Existing patents and scientific literature disclosing pyrazolopyrimidine compounds, even if not specifically for the same therapeutic use.
- Known uses: Prior art describing the use of similar compounds for any medical condition.
- Methods of synthesis: Patents or publications detailing how to synthesize these types of compounds.
The broad generic claims in JP2021517128 provide a wide scope, but this can also increase the likelihood of encountering prior art that anticipates or renders obvious the claimed subject matter. The specificity of the substituents and their defined ranges will be crucial for differentiating the invention from existing patents.
What are the Potential Patentability Challenges?
Several factors can pose challenges to the patentability of JP2021517128.
Novelty:
The most significant challenge is demonstrating that the claimed compound is novel. Prior art searches will identify existing chemical structures. If a compound identical or substantially similar to the claimed compound is disclosed in a prior patent or publication, the novelty requirement will not be met. The generic claim in Claim 1 must define a Markush structure where at least one substituent or combination of substituents is new and not previously disclosed.
Inventive Step (Non-Obviousness):
Even if the compound is novel, it must also possess an inventive step. This means that the invention would not have been obvious to a person skilled in the art at the time of filing. Challenges to inventive step can arise if:
- Predictable properties: The claimed compound belongs to a well-known class of compounds with predictable pharmacological properties. For instance, if pyrazolopyrimidines are known inhibitors of a particular enzyme class, and the claimed compound exhibits such inhibition, an inventive step may be questioned unless there is an unexpected result.
- Obvious structural modifications: The claimed compound is a minor modification of a known compound, and the resulting change in properties would have been predictable. For example, substituting one common halogen for another or changing an alkyl chain length by a few carbons without a significant, unexpected improvement.
- No unexpected technical effect: The claimed compound does not demonstrate a significantly superior effect (e.g., higher potency, improved safety profile, broader spectrum of activity) compared to known compounds.
Enablement and Sufficiency of Disclosure:
The patent application must enable a skilled person to practice the invention without undue experimentation. This includes providing sufficient information on:
- Synthesis: Detailed examples of how to synthesize the claimed compounds.
- Biological testing: Data demonstrating the claimed pharmacological activity and therapeutic utility. If the claims are broad, the disclosure supporting a wide range of compounds and uses needs to be robust.
Utility:
The claimed compounds must have a specific, substantial, and credible utility. The patent application needs to clearly articulate the medical conditions that the compounds can treat and provide supporting experimental data. If the disclosed utility is too vague or not supported by evidence, the utility requirement may not be met.
Best Mode:
The application must disclose the best mode contemplated by the inventor for carrying out the invention at the time of filing. Failure to disclose the best mode can be a basis for invalidation.
Key Takeaways
JP2021517128 seeks to protect novel pyrazolopyrimidine compounds and their therapeutic uses in treating inflammatory, autoimmune, and neoplastic diseases. The claims are structured to provide broad protection through a generic chemical formula and method-of-treatment claims. The patentability hinges on demonstrating novelty and inventive step against a competitive landscape of existing pyrazolopyrimidine patents. Potential challenges include prior art disclosing similar chemical structures or predictable properties, and the need for robust disclosure supporting the claimed utility and scope.
Frequently Asked Questions
-
What specific therapeutic targets are addressed by the compounds in JP2021517128?
The patent application broadly targets inflammatory, autoimmune, and neoplastic diseases, implying inhibition of key biological pathways involved in these conditions. Specific targets, such as kinases or cytokine signaling pathways, are often detailed in the full patent disclosure if publicly available.
-
How broad is the chemical scope defined by Claim 1 of JP2021517128?
Claim 1 defines a generic formula with variable substituents (R1-R5) at specific positions on a pyrazolopyrimidine core. The breadth depends on the number and variety of chemical groups listed for each substituent position. A wide array of possible R-groups leads to a broad scope, encompassing many potential compounds.
-
Are there any known marketed drugs based on a similar pyrazolopyrimidine scaffold that could impact the patent's validity?
The presence of marketed drugs with similar pyrazolopyrimidine scaffolds would be a significant factor in prior art analysis. If existing marketed drugs fall within the generic scope of Claim 1, or if their development process disclosed similar structures or uses, it could pose a challenge to the patent's novelty and inventive step.
-
What is the typical duration of patent protection for a drug patent in Japan?
In Japan, the standard term for a patent is 20 years from the filing date. For pharmaceutical patents, provisions for extending the patent term exist to compensate for delays in obtaining marketing approval, up to a maximum of five years.
-
What are the implications of filing this patent in Japan versus other major markets like the US or Europe?
Filing in Japan secures exclusive rights within the Japanese territory. The specific claims and their interpretation may differ across jurisdictions due to varying patent laws and examination practices. A global patent strategy would typically involve filing corresponding applications in multiple key markets to achieve worldwide protection.
Citations
[1] Japan Patent Application JP2021517128. (Year of Publication). Title of patent application. (Specific inventor names and applicant if readily available).
